Immix Biopharma Files 8-K: Agreements, Equity Sales, Officer Changes
Ticker: IMMX · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1873835
| Field | Detail |
|---|---|
| Company | Immix Biopharma, INC. (IMMX) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $2.37, $9.1 m, $2.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, officer-changes
TL;DR
Immix Biopharma dropped an 8-K: new deals, sold stock, exec shuffle. Watch this space.
AI Summary
Immix Biopharma, Inc. filed an 8-K on September 8, 2025, reporting on several key events. These include entering into a material definitive agreement, unregistered sales of equity securities, and changes in directors or officers. The filing also covers financial statements and exhibits, with the earliest reported event date being September 5, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions at Immix Biopharma, including potential new agreements and equity transactions, which could impact the company's financial structure and leadership.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- September 5, 2025 (date) — Earliest event reported
- September 8, 2025 (date) — Filing date
FAQ
What type of material definitive agreement did Immix Biopharma enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What was the nature of the unregistered sales of equity securities?
The filing reports unregistered sales of equity securities, but the specifics regarding the amount, price, or recipients of these sales are not detailed in the provided text.
Were there any changes in directors or officers reported?
Yes, the filing covers the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements.
What is the principal business address of Immix Biopharma, Inc.?
The principal executive business address is 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064.
What is the SEC file number for Immix Biopharma, Inc.?
The SEC file number for Immix Biopharma, Inc. is 001-41159.
Filing Stats: 1,302 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2025-09-08 16:05:31
Key Financial Figures
- $0.0001 — registered Common Stock, par value of $0.0001 per share IMMX The Nasdaq Stock Mar
- $2.37 — ants"). The purchase price per Share is $2.37. The Private Placement closed on Septem
- $9.1 m — ceiving gross proceeds of approximately $9.1 million, before deducting fees and expens
- $2.00 — ten-year period at an exercise price of $2.00 per share, subject to proportional adju
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex4-1.htm (EX-4.1) — 99KB
- ex10-1.htm (EX-10.1) — 234KB
- ex10-2.htm (EX-10.2) — 109KB
- 0001493152-25-012804.txt ( ) — 752KB
- immx-20250905.xsd (EX-101.SCH) — 3KB
- immx-20250905_lab.xml (EX-101.LAB) — 33KB
- immx-20250905_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 5, 2025, Immix Biopharma, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") and a Registration Rights Agreement (the "Registration Rights Agreement") with certain accredited investors (the "Purchasers"), pursuant to which the Company sold to the Purchasers in a private placement transaction (the "Private Placement") (i) 3,831,216 shares (the "Shares") of the Company's common stock, par value $0.0001 ("Common Stock"), and (ii) non-transferable warrants to purchase 2,873,417 shares of Common Stock (the "Warrants"). The purchase price per Share is $2.37. The Private Placement closed on September 5, 2025 and the Company anticipates receiving gross proceeds of approximately $9.1 million, before deducting fees and expenses payable by the Company. The Company intends to use the proceeds from the Private Placement for working capital and general corporate purposes. The non-transferable Warrants are exercisable over a ten-year period at an exercise price of $2.00 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The non-transferable Warrants are not transferable other than to affiliates of the Purchaser, and are exercisable only for cash consideration. Pursuant to the terms of the Registration Rights Agreement, the Company will prepare and file a resale registration statement with the SEC no later than 30 days after the closing date of the Private Placement. The Registration Rights Agreement also provides that the Company must make certain payments as liquidated damages to the Purchasers if the Company fails to timely file the registration statement or if the registration statement should become unavailable for the resale of the shares of Common Stock, subject to certain exceptions. The Securities Purchase Agreement and Registration Rights Agreement contain customary representations and warr